XML 51 R40.htm IDEA: XBRL DOCUMENT v3.25.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($)
$ in Millions
3 Months Ended 18 Months Ended
Mar. 30, 2025
Mar. 31, 2024
Mar. 30, 2025
Restructuring charges/(credits):      
Employee terminations $ 384 $ (29)  
Asset impairments 173 25  
Exit costs 64 14  
Restructuring charges/(credits) [1] 621 10  
Transaction costs [2] 0 5  
Integration costs and other [3] 57 87  
Restructuring charges and certain acquisition-related costs 678 102  
Additional depreciation––asset restructuring recorded in Cost of sales in our condensed consolidated statements of operations [4] 4 4  
Implementation costs [5] 50 58  
Total costs associated with acquisitions and cost-reduction/productivity initiatives 673 168  
Biopharma [Member]      
Restructuring charges/(credits):      
Restructuring charges/(credits) 617 (37)  
Biopharma [Member] | Manufacturing Optimization Program [Member]      
Restructuring charges/(credits):      
Restructuring charges/(credits) (4)    
Biopharma [Member] | Realigning Our Cost Base Program [Member]      
Restructuring charges/(credits):      
Restructuring charges/(credits) 587   $ 2,500
Other (income)/deductions––net [Member]      
Restructuring charges/(credits):      
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net (59) 3  
Cost of sales [Member]      
Restructuring charges/(credits):      
Implementation costs [5] 20 16  
Selling, informational and administrative expenses [Member]      
Restructuring charges/(credits):      
Implementation costs [5] 6 29  
Research and development expense [Member]      
Restructuring charges/(credits):      
Implementation costs [5] $ 24 $ 13  
[1] In 2025, primarily represents cost-reduction initiatives. In 2024, primarily represented Seagen acquisition-related costs, largely offset by credits for cost-reduction initiatives. Amounts associated with our Biopharma segment: charges of $617 million for the three months ended March 30, 2025 (including charges of $587 million for our Realigning our Cost Base Program and credits of $4 million for our Manufacturing Optimization Program) and credits of $37 million for the three months ended March 31, 2024 for our Realigning our Cost Base Program.
[2] Represents external costs for banking, legal, accounting and other similar services.
[3] Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.
[4] Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[5] Represents incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.